UNITED STATES
                       SECURITIES AND EXCHANGE COMMISSION
                             Washington, D.C. 20549

                                  FORM 10-Q/A
                                 First Amended

(Mark One)
    [ x ] QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES
                              EXCHANGE ACT OF 1934

          For the quarterly period ended __________October 31, 2009____________

                                       or

    [   ] TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES
          EXCHANGE ACT OF 1934

   For the transition period from ______________ to ________________________

              Commission file number ___333-139915________________

                          LIGHTLAKE THERAPEUTICS INC.
--------------------------------------------------------------------------------
             (Exact name of registrant as specified in its charter)

                     Nevada                                       N/A
--------------------------------------------------------------------------------
(State or other jurisdiction of incorporation               (IRS Employer 
                or organization)                         Identification No.)

                    54 Baker Street., 6th Floor                W1U 7BU
--------------------------------------------------------------------------------
            (Address of principal executive offices)          (Zip Code)

                                44-207-034-1943
--------------------------------------------------------------------------------
              (Registrant's telephone number, including area code)


--------------------------------------------------------------------------------
              (Former name, former address and former fiscal year,
                         if changed since last report)

     Indicate  by  check  mark  whether the registrant (1) has filed all reports
required  to  be filed by Section 13 or 15(d) of the Exchange Act of 1934 during
the  preceding  12  months  (or  for such shorter period that the registrant was
required  to  file  such  reports),  and  (2)  has  been  subject to such filing
requirements  for  the  past  90  days.
                                                                Yes [ X ] No [ ]

     Indicate by check mark whether the registrant is a large accelerated filer,
an  accelerated  filer, a non-accelerated filer, or a smaller reporting company.
See  the  definitions  of  "large  accelerated  filer,"  "accelerated filer" and
"smaller  reporting  company"  in  Rule  12b-2  of  the  Exchange  Act.

Large accelerated filer [ ]  Accelerated filer             [ ]
Non-accelerated filer   [ ]  (Do not check if a smaller reporting company)     
                             Smaller reporting company     [X]

     Indicate by check mark whether the registrant is a shell company (as
defined in Rule 12b-2 of the Exchange Act).

                                                                  Yes [ ] No [X]

               APPLICABLE ONLY TO ISSUERS INVOLVED IN BANKRUPTCY
                  PROCEEDINGS DURING THE PRECEDING FIVE YEARS

     Indicate  by  check mark whether the registrant has filed all documents and
reports  required  to  be  filed  by  Sections 12, 13 or 15(d) of the Securities
Exchange  Act  of 1934 subsequent to the distribution of securities under a plan
confirmed  by  a  court.

                      APPLICABLE ONLY TO CORPORATE ISSUERS

     The were 157,658,333 shares of Common Stock outstanding as of October 31,
2009:
                                        

<PAGE>


                         PART I - FINANCIAL INFORMATION


Item 1. Financial Statements.


                          Lightlake Therapeutics, Inc.
                   (Formerly Known as Madrona Ventures, Inc.)
                                 (a Development
                               Stage Enterprise)
                              Financial Statements
                           For the Three Months Ended
                                October 31, 2009
                                      and
                               For the Year Ended
                                 July 31, 2009


<PAGE>

Lightlake Therapeutics, Inc.
(Formerly Known as Madrona Ventures, Inc.)
(a Development Stage Enterprise)
Index to Financial Statements
October 31, 2009
----------------


                                                                        Page
                                                                       Number
                                                                       ------

Report of Independent Registered Public Accounting Firm                   1

Financial Statements:

     Balance Sheet as of October 31, 2009 and July 31, 2009               2

     Statements of Operations for the three months ended 
       October 31, 2009 and year ended July 31, 2009 and for the
       period from Re-entering Development Stage to October 31, 2009      3
       
     Statement of Changes in Shareholders' Deficit
       for the three months ended October 31, 2009 and year 
       ended July 31, 2009 and the period from
       Re-entering Development Stage to October 31, 2009                  4

     Statement of Cash Flows for the for the three months ended 
       October 31, 2009 and year ended July 31, 2009 and for the 
       period from Re-entering Development Stage to October 31, 2009      5
       
     Notes to Financial Statements                                        6


<PAGE>


<TABLE>
<S>                                                                 <C>           <C>
Lightlake Therapeutics, Inc.
( Formerly Known as Madrona Ventures, Inc.)
(a Development Stage Enterprise)
Balance Sheet
October 31, 2009 and July 31, 2009
--------------------------------------------------------------------------------------------

                                                                    October 31,    July 31,
                              Assets                                   2009          2009
                                                                    -----------   ----------
Current assets
  Cash and cash equivalents                                         $      724    $     290
  Other current assets                                                       -            -
                                                                    -----------   ----------
  Total current assets                                                     724          290

Other assets
  Patent and Patent Applications                                        20,333            -
                                                                    -----------   ----------

  Total assets                                                      $   21,057    $     290
                                                                    ===========   ==========

               Liabilities and Shareholders' Deficit
Liabilities
  Accounts payable and accrued liabilities                          $    1,100    $       -
  Due to related party                                                  75,248            -
                                                                    -----------   ----------
  Total liabilities                                                     76,348            -


Stockholders' equity (deficit)
  Common stock; par value $0.001; 200,000,000 shares authorized;
  157,658,333 shares issued and outstanding at October 31, 2009 and
    6,525,000 shares issued and outstanding at October 31, 2008        157,658        6,525
  Additional paid-in capital                                           (81,525)      48,975
  Accumulated deficit during the development stage                    (131,424)     (55,210)
                                                                    -----------   ----------
  Total stockholders' deficit                                          (55,291)         290
                                                                    -----------   ----------
  Total liabilities and stockholders' equity                        $   21,057    $     290
                                                                    ===========   ==========

         The accompanying notes are an integral part of these financial statements.
</TABLE>


<PAGE>


<TABLE>
<S>                                                <C>               <C>            <C>
Lightlake Therapeutics, Inc.
(Formerly Known as Madrona Ventures, Inc.)
(a Development Stage Enterprise)
Statements of Operations
For the Three Months Ended October 31, 2009 and 2008 and the Period From
 Inception (June 21, 2005) to October 31, 2009
----------------------------------------------------------------------------------------------------

                                                                                     From Inception
                                                                                    (June 21, 2005)
                                                   Three Months Ended - October 31,  to October 31,
                                                        2009              2008            2009
                                                   ---------------   -------------- ----------------

Revenues                                           $            -    $         -    $             -

Operating expenses
 General and administrative                                76,214          5,372            135,572
 Mineral interests                                              -              -             39,015
                                                   ---------------   -------------- ----------------
  Total operating expenses                                 76,214          5,372            174,587
                                                   ---------------   -------------- ----------------

Income (loss) from operations                             (76,214)        (5,372)          (174,587)

Other income (expense)
 Debt forgiveness                                               -              -             43,163
                                                   ---------------   -------------- ----------------
  Total other income (expense)                                  -              -             43,163

Income (loss) before provision for income taxes           (76,214)        (5,372)          (131,424)

Provision for income taxes                                      -              -                  -
                                                   ---------------   -------------- ----------------

Net income (loss)                                  $      (76,214)   $    (5,372)   $      (131,424)
                                                   ===============   ============== ================

Basic and fully diluted loss per common share:
 Earnings (loss) per common share                  $        (0.00)   $     (0.00)
                                                   ===============   ==============
Basic and fully diluted weighted average
 common shares outstanding                             94,449,311      6,525,000
                                                   ===============   ==============

         The accompanying notes are an integral part of these financial statements.
</TABLE>


<PAGE>


<TABLE>
<S>                                       <C>          <C>           <C>           <C>            <C>
Lightlake Therapeutics, Inc.
( Formerly Known as Madrona Ventures, Inc.)
(a Development Stage Enterprise)
Statement of Changes in Stockholders' Equity (Deficit)
For the Three Months Ended October 31, 2009 and Year Ended July 31, 2009 and
the Period from Inception (June 21, 2005) to October 31, 2009
--------------------------------------------------------------------------------------------------------------

                                                                                      Deficit
                                                                      Additional     During the
                                                 Common Stock           Paid In     Development
                                             Shares       Amount        Capital        Stage         Total
                                          ------------ ------------- ------------- -------------- ------------

Balance at June 21, 2005                             - $           - $          -  $           -  $         -
                                          ------------ ------------- ------------- -------------- ------------

Balance at July 31, 2005                             -             -            -              -            -
                                          ------------ ------------- ------------- -------------- ------------

Common shares issued for cash
  March 2006 at $0.001 per share             5,000,000         5,000            -                       5,000
  March 2006 at $0.01 per share              1,300,000         1,300       11,700                      13,000
  April 2006 at $0.01 per share                 75,000            75        7,425                       7,500
  May 2006 at $0.01 per share                  150,000           150       29,850                      30,000

Net income (loss)                                                                        (32,125)     (32,125)
                                          ------------ ------------- ------------- -------------- ------------

Balance at July 31, 2006                     6,525,000         6,525       48,975        (32,125)      23,375

Net income (loss)                                                                        (33,605)     (33,605)
                                          ------------ ------------- ------------- -------------- ------------

Balance at July 31, 2007                     6,525,000         6,525       48,975        (65,730)     (10,230)

Net income (loss)                                                                        (17,924)     (17,924)
                                          ------------ ------------- ------------- -------------- ------------

Balance at July 31, 2008                     6,525,000         6,525       48,975        (83,654)     (28,154)

Net income (loss)                                    -             -            -         28,444       28,444
                                          ------------ ------------- ------------- -------------- ------------

Balance at July 31, 2009                     6,525,000 $       6,525 $     48,975  $     (55,210) $       290

Forward Stock Split : 20 for 1             130,500,000 $     130,500 $   (130,500)                          -

Stock Issued for Services                      300,000           300            -                         300

Stock Issued for Acquisition of Patent      20,333,333        20,333            -                      20,333

Net income (loss)                                                                        (76,214)     (76,214)
                                          ------------ ------------- ------------- -------------- ------------

Balance at October 31, 2009                157,658,333 $     157,658 $    (81,525) $    (131,424) $   (55,291)
                                          ============ ============= ============= ============== ============

         The accompanying notes are an integral part of these financial statements.

</TABLE>


<PAGE>


<TABLE>
<S>                                                          <C>              <C>              <C>
Lightlake Therapeutics, Inc.
(Formerly Known as Madrona Ventures, Inc.)
(a Development Stage Enterprise)
Statements of Cash Flows
For the Three Months Ended October 31, 2009 and Year Ended July 31, 2009 and the Period From
 Inception (June 21, 2005) to October 31, 2009
------------------------------------------------------------------------------------------------------------------

                                                                                                  From Inception
                                                                                                 (June 21, 2005)
                                                              Three Months Ended - October 31,    to October 31,
                                                                   2009             2008               2009
                                                              ---------------  ---------------  ------------------

Cash Flows Provided (Used) By Operating Activities
 Net income (loss)                                            $      (76,214)  $       (5,372)  $        (131,424)
 Adjustments to reconcile net income (loss) to net cash
  provided from (used by) operating activities:
   Increase (decrease) in accounts payable                             1,100           (4,045)              1,100
   Increase (decrease) in due to related party                        75,248            9,218              75,248
                                                              ---------------  ---------------  ------------------
    Net cash provided from (used by) operating activities                134             (199)            (55,076)

Cash Flows Provided (Used) By Investing Activities                         -                -                   -

Cash Flows Provided (Used) By Financing Activities
 Issuance of common stock for services                                   300                                  300
 Issuance of common stock for cash                                         -                -              55,500
                                                              ---------------  ---------------  ------------------
  Net cash provided from (used by) financing activities                  300                -              55,800

Net increase (decrease) in cash and cash equivalents                     434             (199)                724
Cash and cash equivalents, beginning of year                             290              206                   -
                                                              ---------------  ---------------  ------------------
Cash and cash equivalents, end of year                        $          724   $            7   $             724
                                                              ===============  ===============  ==================

Supplemental disclosure
 Interest paid during the period                              $            -   $            -   $               -
                                                              ===============  ===============  ==================

Non-Cash Transactions
 In August, 2009, the Company acquired a Patent and Patent Applications through the issuance of 20,333,000 Common shares.


                    The accompanying notes are an integral part of these financial statements.
</TABLE>


<PAGE>

Lightlake Therapeutics, Inc.
(Formerly Known As Madrona Ventures, Inc.)
(A Development Stage Enterprise)

Notes to Financial Statements
October 31, 2009
--------------------------------------------------------------------------------

1.   Organization, Description of Business, and Basis of Accounting

     Business Organization

     Lightlake Therapeutics, Inc., (formerly known as Madrona Ventures,
     Inc.) (the Company) was originally incorporated in the State of Nevada on
     June 21, 2005. On September 16, 2009, the Company changed its' name to
     Lightlake Therapeutics, Inc. The Company's fiscal year end is July 31. The
     company is currently in the development stage and to date its' activities
     have been limited to capital formation. The Company has limited assets and
     no revenue and in accordance with SFAS No.7, is considered a Development
     Stage Company.

     Accounting Basis

     Interim Financial Statements

     The accompanying unaudited condensed consolidated financial statements
     have  been  prepared  in  accordance  with  accounting principles generally
     accepted  in  the  United  States  of  America,  pursuant  to the rules and
     regulations  of  the  Securities  and  Exchange Commission. All significant
     intercompany  balances  and  transactions  have  been  eliminated.  These
     financial  statements  do not include all information and notes required by
     accounting  principles  generally  accepted in the United States of America
     for  complete  financial  statements.  It is recommended that these interim
     unaudited  condensed  consolidated  financial  statements  be  read  in
     conjunction  with  the  consolidated financial statements and notes thereto
     included  in  the  Company's Annual Report on Form 10-K for the fiscal year
     ended  July  31,  2009.

     In  the  opinion  of  management,  all adjustments (consisting only of
     normal  recurring  accruals)  considered  necessary for a fair presentation
     have  been  included.  Operating  results  for the three month period ended
     October 31, 2009 are not necessarily indicative of the results which may be
     expected  for  any other interim periods or for the year ending October 31,
     2010. The preparation of financial statements in conformity with accounting
     principles  generally  accepted  in  the  United States of America requires
     management  to  make  estimates  and  assumptions  that affect the reported
     amounts  of  assets and liabilities and disclosure of contingent assets and
     liabilities  at  the  date  of  the  financial  statements and the reported
     amounts  of  revenues  and  expenses  during  the  reporting period. Actual
     results  could  differ  from  these  estimates.

     These  financial statements have been prepared on the accrual basis of
     accounting  following  generally  accepted  accounting  principles  of  the
     country-regionplaceUnited  States  of  America  consistently  applied.

2.   Patent and Patent Applications

     On  August  24, 2009, the Company acquired European Patent EP1681057B1
     and  U.S.  Patent Application 11/031,534 through the issuance of 20,333,000
     of  its'  common  stock.

<PAGE>

Lightlake Therapeutics, Inc.
(Formerly Known As Madrona Ventures, Inc.)
(A Development Stage Enterprise)
Notes to Financial Statements
October 31, 2009
--------------------------------------------------------------------------------

3.   Going Concern

     The  accompanying financial statements have been prepared assuming the
     Company  will  continue  as  a  going  concern,  which  contemplates  the
     realization  of  assets  and  the  liquidation of liabilities in the normal
     course  of  business.  This  raises  substantial  doubt about the Company's
     ability  to  continue as a going concern. These financial statements do not
     include  any  adjustments  that  might  result  from  this  uncertainty

4.   Capital  Stock

     The Company has 200,000,000 common shares authorized at a par value of
     $0.001. At October 31, 2009, there were 157,658,333 shares issued and
     outstanding. The Company has no other classes of shares authorized for
     issuance.

     At October 31, 2009, there were no outstanding stock options or warrants.


5.   Common  Stock  Purchase  Agreement

On  October  31,  2009,  the Company completed a common stock purchase agreement
(the  Pelikin  Agreement) whereby Pelikin Group acquired 5,000,000 common shares
of the Company's common stock from Belmont Partners.  Following the transaction,
Pelikin  Group controls approximately 76.6% of the Company's outstanding capital
stock.  Concurrent  with  the  agreement,  Mr.  Sei Ki was named to the Board of
Directors  as  well  as  President  and Secretary of the Company, and Mr. Joseph
Muese  resigned  from  all  positions  held  in  the  Company.


6.   Income  Taxes

     The Company has net operating loss carryforwards that were derived
     solely from operating losses from prior years. These amounts can be carried
     forward to offset future taxable income for a period of 20 years for each
     tax year's loss. No provision was made for federal income taxes as the
     Company has significant net operating losses.

     The operating losses derive a deferred tax asset of approximately
     $30,277 and $18,800 at October 31, 2009 and July 31, 2008, respectively. At
     October 31, and July 31,2009, the Company has established a valuation
     allowance equal to the deferred tax assets as there is no assurance that
     the Company will generate future taxable income to utilize these assets.

     Due to the provisions of Internal Revenue Code Section 338, the
     Company may have no net operating loss carryforwards available to offset
     financial statement or tax return taxable income in future periods as a
     result of a change in control involving 50 percentage points or more of the
     issued and outstanding securities of the Company.

7.   Related  Party  Transactions

     The Company's Director and former officer advanced funds to the
     Company for working capital needs in the amount of $ 75,248. The amounts
     were non-interest bearing, unsecured, with no stated terms or repayment.


<PAGE>


I
tem 2. Management's Discussion and Analysis of Financial Condition and Results
of Operations.

FORWARD LOOKING STATEMENTS

Statements  contained  herein which are not historical facts are forward-looking
statements  as  that term is defined by the Private Securities Litigation Reform
Act  of  1995.  Although the Company believes that the expectations reflected in
such  forward-looking  statements are reasonable, forward-looking statements are
subject  to  risks  and  uncertainties that could cause actual results to differ
from  those  projected.  The Company cautions investors that any forward-looking
statements  made  by  the  Company  are not guarantees of future performance and
actual  results  may  differ  materially  from  those  in  the  forward-looking
statements. Such risks and uncertainties include without limitation: established
competitors  who  have  substantially  greater financial resources and operating
histories,  regulatory  delays  or  denials,  ability  to  compete as a start-up
company  in  a  highly  competitive  market  and  access  to sources of capital.

The  following  discussion  and  analysis should be read in conjunction with our
financial  statements  and notes thereto included elsewhere in this Form 10-Q/A.
Except  for  the historical information contained herein, the discussion in this
Form  10-Q/A  contains  certain forward-looking statements that involve risk and
uncertainties,  such  as  statements  of  plans,  objectives,  expectations  and
intentions. The cautionary statements made in this Form 10-Q/A should be read as
being  applicable to all related forward-looking statements wherever they appear
in  this  Form 10-Q/A. The Company's actual results could differ materially from
those  discussed  here.

The  Company  was  incorporated  in  the State of Nevada on June 21, 2005 and On
September  16,  2009,  the  Company changed its' name to Lightlake Therapeutics,
Inc.  The  Company's  fiscal  year  end  is  July  31 and is a development stage
Company.  Lightlake  Therapeutics  Inc.  is a drug discovery company focusing on
developing  new  and  innovative  solutions  to  obesity  and  eating disorders.

During  the  year  ended  July  31,  2009,  the company carried out very limited
operations  and  on  June  26,  2009  Belmont  Partners  (Belmont)  acquired  a
controlling interest of approximately 76.6% of the Company's outstanding shares.
(ref:  Form  8-K  filing date June 26, 2009) On July 31, 2009, the Pelikin Group
acquired  the 5,000,000 shares from Belmont and will be continuing operations as
a  pharmaceutical company focusing on developing new and innovative solutions to
obesity  and  eating  disorders.

PLAN OF OPERATION

Our plan of operation for the next twelve months is to pursue the Phase 2
clinical trials in Helsinki, Finland on the user patents that were acquired by
the company from Dr. David Sinclair, in exchange for 20,333,333 restricted
common shares on August 24, 2009.  (see Exhibit 5, Sinclair Agreement Form 10-K)
The safe and effective treatment is a proprietary patented pharmaceutical
medicine-based behaviour program pioneered by Dr. David Sinclair

We have not attained profitable operations and are dependent upon obtaining
financing to pursue the Phase 2 clinical trials in Helsinki, Finland.  For these
reasons our auditors believe that there is substantial doubt that we will be
able to continue as a going concern.

LIQUIDITY AND CAPITAL RESOURCES

Our cash reserves are not sufficient to meet our obligations for the next twelve
month  period.  As a result, we will need to seek additional funding in the near
future.  We  currently  do  not  have a specific plan of how we will obtain such
funding;  however,  we anticipate that additional funding will be in the form of
equity  financing  from the sale of our common stock. We may also seek to obtain
short-term  loans  from  our  directors, although no such arrangements have been
made.  At this time, we cannot provide investors with any assurance that we will
be  able  to  obtain  sufficient  funding  from  the sale of our common stock or
through  a  loan from our directors to meet our obligations over the next twelve
months.  We  do  not  have  any  arrangements  in  place  for  any future equity
financing.

RESULTS OF OPERATIONS

We  did  not  earn any revenues during the three month period ending October 31,
2009 and have generated no revenues since inception.  We have incurred operating
expenses  in the amount of $76,214 for the three month period ending October 31,
2009.  For  the  same  three  month period ending October 31, 2008 our operating
expenses  was  $5,372.

Our  net loss for the three month period ending October 31, 2009 was $76,214 and
our  net  loss  from  inception  through  October  31,  2009  was  $131,424.

                                        

<PAGE>
At October 31, 2009, we had assets of $21,057 and at the same date current
liabilities of $76,348.

The following table provides selected financial data about our Company as at
October 31, 2009 and July 31, 2009.


Balance Sheet Data:            10/31/09            7/31/09
-------------------            -------             -------

Cash                           $    724            $   290
Total assets                   $ 21,057            $   290
Total Liabilities              $ 76,348            $     0
Shareholder's equity           $ 21,057            $   290

We  have  not  attained  profitable  operations and are dependent upon obtaining
financing  to  pursue the clinical trials in Helsinki, Finland.  In their report
on  our  audited  financial  statements as at July 31, 2009, our auditors raised
substantial doubt about our ability to continue as a going concern unless we are
able  to  raise  additional  capital  and  ultimately  to  generate  profitable
operations.

SIGNIFICANT ACCOUNTING POLICIES
It  is suggested that these financial statements be read in conjunction with our
July 31, 2009 audited financial statements and notes thereto, which can be found
in  our  Form  10-K  annual filing and amendments thereto, on the SEC website at
www.sec.gov  under  our  SEC  File  Number  333-139915.

Our significant accounting policies are as follows:

PATENT OWNERSHIP

The user patents that were acquired by the company from Dr. David Sinclair, in
exchange for 20,333,333 restricted common shares on August 24, 2009.  (see
Exhibit 5, Sinclair Agreement Form 10-K) The safe and effective treatment is a
proprietary patented pharmaceutical medicine-based behaviour program pioneered
by Dr. David Sinclair.  The company plans to file and obtain the necessary
requirements to conduct Phase II clinical trials in Helsinki, Finland.  There is
no guarantee that we will obtain the approval from the Finnish authorities to
conduct the trials and the company will need to obtain the required financing if
granted the approvals to conduct the trials.  To date the company has not been
granted the approvals to conduct the trials.



I
tem 3. Quantitative and Qualitative Disclosures About Market Risk.

As a smaller reporting Company we are not required to provide the disclosure
required by this item.


Item 4. Controls and Procedures.

Under  the  supervision  and with the participation of our management, including
our  principal  executive  officer  and the principal financial officer, we have
conducted  an evaluation of the effectiveness of the design and operation of our
disclosure  controls and procedures, as defined in Rules 13a-15(e) and 15d-15(e)
under  the  Securities  and  Exchange  Act  of 1934, as of the end of the period
covered  by  this  report.  Based  on  this  evaluation, our principal executive
officer and principal financial officer concluded as of the evaluation date that
our  disclosure  controls  and  procedures were effective such that the material
information  required  to  be included in our Securities and Exchange Commission
reports  is  accumulated  and  communicated  to  our  management,  including our
principal  executive  and financial officer, recorded, processed, summarized and
reported  within  the  time periods specified in SEC rules and forms relating to
our company, particularly during the period when this report was being prepared.

CHANGES IN INTERNAL CONTROLS OVER FINANCIAL REPORTING

There have been no changes in our internal control over financial reporting that
occurred  during  the  last  fiscal  quarter  ended  April  30,  2009  that have
materially affected, or are reasonably likely to materially affect, our internal
control  over  financial  reporting.

                                        

<PAGE>


                          PART II - OTHER INFORMATION



ITEM 1. LEGAL PROCEEDINGS

We are not currently involved in any legal proceedings and we are not aware of
any pending or potential legal actions.


ITEM 2. UNREGISTERED SALES OF EQUITY SECURITIES AND USE OF PROCEEDS
There were no sales of unregistered securities during the period of this report.


ITEM 3. DEFAULTS UPON SENIOR SECURITIES

There were no defaults upon senior securities during the period of this report.


ITEM 4. SUBMISSION OF MATTERS TO A VOTE OF SECURITY HOLDERS

There were no matters submitted to a vote of security holders during the period
covered by this report.


ITEM 5. OTHER INFORMATION

On August 5, 2009 the Company increased its authorized shares from 75,000,000 to
200,000,000.

On August 20, 2009 the Company's shares increased by a 20 for 1 split.

On September 16 2009 the Company changed its name from Madrona Ventures Inc. to
Lightlake Therapeutics Inc. and the new symbol of LLTP became effective October
7, 2009.

On October 22, 2009 the Company filed a Form 8-K/A noting the dismissal of our
former auditing firm of Dale Matheson Carr-Hilton Labonte LLP. And the
engagement of  the accounting firm of PS Stephenson & Co., P.C., CPA on August
17 2009 respectively.

On October 23, 2009 Mr. Seijin Ki resigned as his position as CEO and Dr. Roger
Crystal was appointed as the President and CEO.  This Form 8-K was filed October
23, 2009.

                                        

<PAGE>


ITEM 6. EXHIBITS

The following exhibits are included with this quarterly filing. Those marked
with an asterisk and required to be filed hereunder, are incorporated by
reference and can be found in their entirety in our form SB-2 Registration
Statement, filed under SEC File Number 333-146934, at the SEC website at
www.sec.gov:

          Exhibit
          Number                        Description
          ------                        -----------

            3.1          Articles of Incorporation*
            3.2          Bylaws*
           31.1          Rule 13a-14(a)/14a-15(d) Certification
           31.2          Rule 13a-14(a)/14a-15(d) Certification
           32.1          Certification pursuant to 18 U.S.C. 1350
           32.2          Certification pursuant to 18 U.S.C. 1350


                                   SIGNATURES

     Pursuant  to  the  requirements of the Securities Exchange Act of 1934, the
registrant  has  duly  caused  this  report  to  be  signed on its behalf by the
undersigned  thereunto  duly  authorized.


                                LIGHTLAKE THERAPEUTICS INC.

Date March 15, 2010             By:  /s/ Dr. Roger Crystal
                                     -------------------------------------------
                                     Name  Dr. Roger Crystal
                                     Title Chief Executive Officer and President



Date March 15, 2010             By:  /s/ Seijin Ki
                                     -------------------------------------------
                                     Name Seijin Ki
                                     Title Chief Financial Officer and Director


                                       



EXHIBIT  31.1


                                 CERTIFICATION
                           Pursuant to 18 U.S.C. 1350
                (Section 302 of the Sarbanes-Oxley Act of 2002)

I,  Dr.  Roger  Crystal, Chief Executive Officer of Lightlake Therapeutics Inc.,
certify  that:

1.  I  have  reviewed  this  Quarterly  Report  on  Form  10-Q/A  of  Lightlake
Therapeutics  Inc.;

2.   Based on my knowledge, this report does not contain any untrue statement of
a  material  fact  or  omit  to  state  a  material  fact  necessary to make the
statements  made, in light of the circumstances under which such statements were
made,  not  misleading  with  respect  to  the  period  covered  by this report;

3.   Based  on  my  knowledge,  the  financial  statements,  and other financial
information included in this report, fairly present in all material respects the
financial  condition,  results of operations and cash flows of the registrant as
of,  and  for,  the  periods  presented  in  this  report;

4.   The  registrant's  other  certifying  officer(s)  and I are responsible for
establishing  and  maintaining disclosure controls and procedures (as defined in
Exchange Act Rules 13a-15(e) and 15d-15(e)) and internal control over  financial
reporting  (as  defined  in  Exchange Act Rules 13a-15(f) and 15d-15(f)) for the
registrant  and  have:

     a)   Designed such disclosure controls and procedures,
 or caused such
          disclosure controls and procedures to be designed under our
          supervision, to ensure that material information relating to the
          registrant, including its consolidated subsidiaries, is made known to
          me by others within those entities, particularly during the period in
          which this report is being prepared;

     b)   Designed such internal control over financial reporting, or
          caused such internal control over financial reporting to be designed
          under our supervision, to provide reasonable assurance regarding the
          reliability of financial reporting and the preparation of financial
          statements for external purposes in accordance with generally accepted
          accounting principles;

     c)   Evaluated the effectiveness of the registrant's disclosure
          controls and procedures and presented in this report our conclusions
          about the effectiveness of the disclosure controls and procedures, as
          of the end of the period covered by this report based on such
          evaluation; and

     d)   Disclosed in this report any change in the registrant's internal
          control over financial reporting that occurred during the registrant's
          most recent fiscal quarter (the registrant's fourth fiscal quarter in
          the case of an annual report) that has materially affected, or is
          reasonably likely to materially affect, the registrant's internal
          control over financial reporting; and

5.   The registrant's other certifying officer(s) and I have disclosed, based on
our  most recent evaluation of internal control over financial reporting, to the
registrant's  auditors  and  the  audit  committee  of the registrant's board of
directors  (or  persons  performing  the  equivalent  functions):

     a)   All significant deficiencies and material weaknesses in the
          design or operation of internal control over financial reporting which
          are reasonably likely to adversely affect the registrant's ability to
          record, process, summarize and report financial information; and

     b)   Any fraud, whether or not material, that involves management or
          other employees who have a significant role in the registrant's
          internal control over financial reporting.


Date:  03/15/10                              By:  /s/  Dr.  Roger  Crystal
                                                  ------------------------------
                                                  Dr.  Roger  Crystal
                                                  Chief  Executive  Officer

EXHIBIT  31.2


                                 CERTIFICATION
                           Pursuant to 18 U.S.C. 1350
                (Section 302 of the Sarbanes-Oxley Act of 2002)

I,  Seijin  Ki,  Chief Financial Officer of Lightlake Therapeutics Inc., certify
that:

1.   I  have  reviewed  this  Quarterly  Report  on  Form  10-Q/A  of  Lightlake
Therapeutics  Inc.;

2.   Based on my knowledge, this report does not contain any untrue statement of
a  material  fact  or  omit  to  state  a  material  fact  necessary to make the
statements  made, in light of the circumstances under which such statements were
made,  not  misleading  with  respect  to  the  period  covered  by this report;

3.   Based  on  my  knowledge,  the  financial  statements,  and other financial
information included in this report, fairly present in all material respects the
financial  condition,  results of operations and cash flows of the registrant as
of,  and  for,  the  periods  presented  in  this  report;

4.   The  registrant's  other  certifying  officer(s)  and I are responsible for
establishing  and  maintaining disclosure controls and procedures (as defined in
Exchange Act Rules 13a-15(e) and 15d-15(e)) and internal control over  financial
reporting  (as  defined  in  Exchange Act Rules 13a-15(f) and 15d-15(f)) for the
registrant  and  have:

     a)   Designed such disclosure controls and procedures, or
 caused such
          disclosure controls and procedures to be designed under our
          supervision, to ensure that material information relating to the
          registrant, including its consolidated subsidiaries, is made known to
          me by others within those entities, particularly during the period in
          which this report is being prepared;

     b)   Designed such internal control over financial reporting, or
          caused such internal control over financial reporting to be designed
          under our supervision, to provide reasonable assurance regarding the
          reliability of financial reporting and the preparation of financial
          statements for external purposes in accordance with generally accepted
          accounting principles;

     c)   Evaluated the effectiveness of the registrant's disclosure
          controls and procedures and presented in this report our conclusions
          about the effectiveness of the disclosure controls and procedures, as
          of the end of the period covered by this report based on such
          evaluation; and

     d)   Disclosed in this report any change in the registrant's internal
          control over financial reporting that occurred during the registrant's
          most recent fiscal quarter (the registrant's fourth fiscal quarter in
          the case of an annual report) that has materially affected, or is
          reasonably likely to materially affect, the registrant's internal
          control over financial reporting; and

5.   The registrant's other certifying officer(s) and I have disclosed, based on
our  most recent evaluation of internal control over financial reporting, to the
registrant's  auditors  and  the  audit  committee  of the registrant's board of
directors  (or  persons  performing  the  equivalent  functions):

     a)   All significant deficiencies and material weaknesses in the
          design or operation of internal control over financial reporting which
          are reasonably likely to adversely affect the registrant's ability to
          record, process, summarize and report financial information; and

     b)   Any fraud, whether or not material, that involves management or
          other employees who have a significant role in the registrant's
          internal control over financial reporting.


Date:  3/15/10                               By:  /s/ Seijin Ki
                                                  ------------------------------
                                                  Seijin Ki
                                                  Chief Financial Officer

EXHIBIT  32.1


                                 CERTIFICATION
                           Pursuant to 18 U.S.C. 1350
                (Section 906 of the Sarbanes-Oxley Act of 2002)

In connection with the Quarterly Report on Form 10-Q/A of Lightlake Therapeutics
Inc.  (the"Company")  for  the  year  ended  July  31,  2008,  as filed with the
Securities  and Exchange Commission on the date hereof (the "Report"), Dr. Roger
Crystal,  as  Chief Executive Officer of the Company, hereby certifies, pursuant
to 18 U.S.C. ss.1350, as adopted pursuant to ss.906 of the Sarbanes-Oxley Act of
2002,  that:

     (1)  The  Report  fully  complies with the requirements of Section 13(a) or
          15(d)  of  the  Securities  Exchange  Act  of  1934;  and

     (2)  The  information  contained  in  the  Report  fairly  presents, in all
          material  respects,  the financial condition and results of operations
          of  the  Company.


Date:  3/15/10                          By:  /s/ Dr. Roger Crystal
                                             -----------------------------------
                                             Dr. Roger Crystal
                                             Chief Executive  Officer


This  certification  accompanies  each  Report  pursuant  to  ss.  906  of  the
Sarbanes-Oxley  Act  of 2002 and shalL not, except to the extent required by the
Sarbanes-Oxley Act of 2002, be deemed filed by the Company for purposes of ss.18
of  the  Securities  Exchange  Act  of  1934,  as  amended.

A  signed  original  of  this written statement required by Section 906 has been
provided to the Company and will be retained
 by the Company and furnished to the
Securities  and  Exchange  Commission  or  its  staff  upon  request.

EXHIBIT  32.2


                                 CERTIFICATION
                           Pursuant to 18 U.S.C. 1350
                (Section 906 of the Sarbanes-Oxley Act of 2002)

In connection with the Quarterly Report on Form 10-Q/A of Lightlake Therapeutics
Inc.  (the  "Company")  for  the  year  ended  July  31, 2008, as filed with the
Securities and Exchange Commission on the date hereof (the "Report"), Seijin Ki,
as  Chief  Financial  Officer  of  the Company, hereby certifies, pursuant to 18
U.S.C. ss.1350, as adopted pursuant to ss.906 of the Sarbanes-Oxley Act of 2002,
that:

     (1)  The  Report  fully  complies with the requirements of Section 13(a) or
          15(d)  of  the  Securities  Exchange  Act  of  1934;  and

     (2)  The  information  contained  in  the  Report  fairly  presents, in all
          material  respects,  the financial condition and results of operations
          of  the  Company.


Date:  3/15/10                          By:  /s/ Seijin Ki
                                             -----------------------------------
                                             Seijin Ki
                                             Chief Financial Officer


This  certification  accompanies  each  Report  pursuant  to  ss.  906  of  the
Sarbanes-Oxley  Act  of 2002 and shall not, except to the extent required by the
Sarbanes-Oxley Act of 2002, be deemed filed by the Company for purposes of ss.18
of  the  Securities  Exchange  Act  of  1934,  as  amended.

A  signed  original  of  this written statement required by Section 906 has been
provided to the Company and will be retained by the Company and furnished
 to the
Securities  and  Exchange  Commission  or  its  staff  upon  request.